10x Genomics (TXG) Accumulated Expenses (2018 - 2025)
10x Genomics (TXG) has disclosed Accumulated Expenses for 8 consecutive years, with $42.5 million as the latest value for Q4 2025.
- Quarterly Accumulated Expenses rose 3.24% to $42.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.5 million through Dec 2025, up 3.24% year-over-year, with the annual reading at $42.5 million for FY2025, 3.24% up from the prior year.
- Accumulated Expenses hit $42.5 million in Q4 2025 for 10x Genomics, up from $37.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $62.0 million in Q3 2022 to a low of $17.6 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $37.3 million across 5 years, with a median of $36.7 million in 2023.
- Biggest five-year swings in Accumulated Expenses: surged 152.08% in 2022 and later tumbled 57.96% in 2023.
- Year by year, Accumulated Expenses stood at $31.6 million in 2021, then surged by 89.02% to $59.8 million in 2022, then decreased by 5.24% to $56.6 million in 2023, then dropped by 27.33% to $41.2 million in 2024, then grew by 3.24% to $42.5 million in 2025.
- Business Quant data shows Accumulated Expenses for TXG at $42.5 million in Q4 2025, $37.1 million in Q3 2025, and $26.1 million in Q2 2025.